Chinese Covid vaccine far less effective , sparking concerns

knowledge88

Minister (2k+ posts)
(CNN)A leading Chinese Covid-19 vaccine developed by Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of Sao Paulo Tuesday.

While the number exceeds the threshold required for regulatory approval, it falls far below the 78% previously announced, raising questions as to the veracity of the data and fueling skepticism over the apparent lack of transparency regarding Chinese vaccines.
Analysts said the efficacy rate of Sinovac's Coronavac vaccine in Brazil -- the lowest among its global competitors -- could affect international confidence in Chinese-made vaccines and hamper Beijing's effort to repair its image from its early mishandling of the initial outbreak by providing Covid-19 vaccines to developing countries.
"The Butantan Institute and the Government of Sao Paulo report that the coronavirus vaccine achieved a 50.38% overall efficacy rate in the clinical study conducted in Brazil, in addition to (an efficacy rate of) 78% for mild cases and 100% for moderate and severe cases of Covid-19. All rates are higher than the 50% level required by the WHO (World Health Organization)," the statement released Tuesday said.

The razor-thin margin for regulatory approval is likely to lead to concern among scientists, given that last week the Butantan institute released partial "clinical efficacy" results celebrating 78% to 100% efficacy in preventing infections.

The state body financed the phase 3 trials of the vaccine, which involved 13,000 health workers across eight Brazilian states.
Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.


Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.

"Regarding the overall efficacy of the analysis, we met the requirements of the World Health Organization with 50.38%," Ricardo Palacios, medical director for clinical research at the Butantan biomedical center in Sao Paulo said Tuesday during a news conference.
However, on Tuesday, high-ranking members of the Brazilian Health Ministry told CNN affiliate CNN Brasil that "the effectiveness is borderline," and that because "It is at the limit. We have to wait for ANVISA (Brazilian Health Regulatory Agency) to evaluate."
A representative of Sinovac said the company is discussing the result but declined to give further comment. The final efficacy rate of the vaccine will be determined by China's drug regulator, the National Medical Production Administration, according to the representative.

 
Advertisement

MRT.abcd

Senator (1k+ posts)
different results from different regions for Chinese vaccines. Pakistan is running its own trial. PK should make trial results public
 

Will_Bite

Chief Minister (5k+ posts)
On a similar note, Pfizer vaccine may have better results, but their side effects are still unknown. Few months of testing are not nearly enough to determine how the artificial protein toys with DNA
 

Hate_Nooras

Chief Minister (5k+ posts)
I think with so much propaganda against vaccines by Desis through WhatsApp and Facebook, what difference will it practically make to the takeup.
 

mskhan

Minister (2k+ posts)
Well this could also be a propaganda, why I think so, is because their vaccine must be good, as we didn’t hear about any more second waves etc in China,

and remember China is where the virus started.

China total infections 87,700

UK total infections 3.16 million just deaths 83,260

the results speaks for itself
 

barzi

Politcal Worker (100+ posts)
(CNN)A leading Chinese Covid-19 vaccine developed by Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of Sao Paulo Tuesday.

While the number exceeds the threshold required for regulatory approval, it falls far below the 78% previously announced, raising questions as to the veracity of the data and fueling skepticism over the apparent lack of transparency regarding Chinese vaccines.
Analysts said the efficacy rate of Sinovac's Coronavac vaccine in Brazil -- the lowest among its global competitors -- could affect international confidence in Chinese-made vaccines and hamper Beijing's effort to repair its image from its early mishandling of the initial outbreak by providing Covid-19 vaccines to developing countries.
"The Butantan Institute and the Government of Sao Paulo report that the coronavirus vaccine achieved a 50.38% overall efficacy rate in the clinical study conducted in Brazil, in addition to (an efficacy rate of) 78% for mild cases and 100% for moderate and severe cases of Covid-19. All rates are higher than the 50% level required by the WHO (World Health Organization)," the statement released Tuesday said.

The razor-thin margin for regulatory approval is likely to lead to concern among scientists, given that last week the Butantan institute released partial "clinical efficacy" results celebrating 78% to 100% efficacy in preventing infections.

The state body financed the phase 3 trials of the vaccine, which involved 13,000 health workers across eight Brazilian states.
Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.


Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.

"Regarding the overall efficacy of the analysis, we met the requirements of the World Health Organization with 50.38%," Ricardo Palacios, medical director for clinical research at the Butantan biomedical center in Sao Paulo said Tuesday during a news conference.
However, on Tuesday, high-ranking members of the Brazilian Health Ministry told CNN affiliate CNN Brasil that "the effectiveness is borderline," and that because "It is at the limit. We have to wait for ANVISA (Brazilian Health Regulatory Agency) to evaluate."
A representative of Sinovac said the company is discussing the result but declined to give further comment. The final efficacy rate of the vaccine will be determined by China's drug regulator, the National Medical Production Administration, according to the representative.

Flu ki vaccine bhi 40% effective hay ,guzishta 15 Saal se,aur covid vaccine agar 20% Kam kargai Tu ok hi hay
CNN ko ziada serious mat lo
 

surfer

Minister (2k+ posts)
(CNN)A leading Chinese Covid-19 vaccine developed by Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of Sao Paulo Tuesday.

While the number exceeds the threshold required for regulatory approval, it falls far below the 78% previously announced, raising questions as to the veracity of the data and fueling skepticism over the apparent lack of transparency regarding Chinese vaccines.
Analysts said the efficacy rate of Sinovac's Coronavac vaccine in Brazil -- the lowest among its global competitors -- could affect international confidence in Chinese-made vaccines and hamper Beijing's effort to repair its image from its early mishandling of the initial outbreak by providing Covid-19 vaccines to developing countries.
"The Butantan Institute and the Government of Sao Paulo report that the coronavirus vaccine achieved a 50.38% overall efficacy rate in the clinical study conducted in Brazil, in addition to (an efficacy rate of) 78% for mild cases and 100% for moderate and severe cases of Covid-19. All rates are higher than the 50% level required by the WHO (World Health Organization)," the statement released Tuesday said.

The razor-thin margin for regulatory approval is likely to lead to concern among scientists, given that last week the Butantan institute released partial "clinical efficacy" results celebrating 78% to 100% efficacy in preventing infections.

The state body financed the phase 3 trials of the vaccine, which involved 13,000 health workers across eight Brazilian states.
Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.


Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.

"Regarding the overall efficacy of the analysis, we met the requirements of the World Health Organization with 50.38%," Ricardo Palacios, medical director for clinical research at the Butantan biomedical center in Sao Paulo said Tuesday during a news conference.
However, on Tuesday, high-ranking members of the Brazilian Health Ministry told CNN affiliate CNN Brasil that "the effectiveness is borderline," and that because "It is at the limit. We have to wait for ANVISA (Brazilian Health Regulatory Agency) to evaluate."
A representative of Sinovac said the company is discussing the result but declined to give further comment. The final efficacy rate of the vaccine will be determined by China's drug regulator, the National Medical Production Administration, according to the representative.

The first dose of Pfizer vaccine is approx 52% effective. UK has cancelled 2nd doses in order that more people can get vaccinated. It’s all relative.
 

Eyeaan

Chief Minister (5k+ posts)
(CNN)A leading Chinese Covid-19 vaccine developed by Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of Sao Paulo Tuesday.

While the number exceeds the threshold required for regulatory approval, it falls far below the 78% previously announced, raising questions as to the veracity of the data and fueling skepticism over the apparent lack of transparency regarding Chinese vaccines.
Analysts said the efficacy rate of Sinovac's Coronavac vaccine in Brazil -- the lowest among its global competitors -- could affect international confidence in Chinese-made vaccines and hamper Beijing's effort to repair its image from its early mishandling of the initial outbreak by providing Covid-19 vaccines to developing countries.
"The Butantan Institute and the Government of Sao Paulo report that the coronavirus vaccine achieved a 50.38% overall efficacy rate in the clinical study conducted in Brazil, in addition to (an efficacy rate of) 78% for mild cases and 100% for moderate and severe cases of Covid-19. All rates are higher than the 50% level required by the WHO (World Health Organization)," the statement released Tuesday said.

The razor-thin margin for regulatory approval is likely to lead to concern among scientists, given that last week the Butantan institute released partial "clinical efficacy" results celebrating 78% to 100% efficacy in preventing infections.

The state body financed the phase 3 trials of the vaccine, which involved 13,000 health workers across eight Brazilian states.
Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.


Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.

"Regarding the overall efficacy of the analysis, we met the requirements of the World Health Organization with 50.38%," Ricardo Palacios, medical director for clinical research at the Butantan biomedical center in Sao Paulo said Tuesday during a news conference.
However, on Tuesday, high-ranking members of the Brazilian Health Ministry told CNN affiliate CNN Brasil that "the effectiveness is borderline," and that because "It is at the limit. We have to wait for ANVISA (Brazilian Health Regulatory Agency) to evaluate."
A representative of Sinovac said the company is discussing the result but declined to give further comment. The final efficacy rate of the vaccine will be determined by China's drug regulator, the National Medical Production Administration, according to the representative.

We'll see big pharma games backed by the governments, because often big pharma controls many in media and government officials. They have influence in health organizations as well. UN has big support funds for vaccine that pharma has eyes on.
Chinese or Indian vaccine are first challenge to them.
I'm not to blindly accept chinese or Indian claims since they also have monetary interests but CNN type preliminary reports are no good and hard to see what are their true motivations or authenticity. Only reliable scientific organizations can give true comparative analysis.
Pak should rely upon local testing and analysis - and of course cost is an issue as well.
 

surfer

Minister (2k+ posts)
(CNN)A leading Chinese Covid-19 vaccine developed by Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of Sao Paulo Tuesday.

While the number exceeds the threshold required for regulatory approval, it falls far below the 78% previously announced, raising questions as to the veracity of the data and fueling skepticism over the apparent lack of transparency regarding Chinese vaccines.
Analysts said the efficacy rate of Sinovac's Coronavac vaccine in Brazil -- the lowest among its global competitors -- could affect international confidence in Chinese-made vaccines and hamper Beijing's effort to repair its image from its early mishandling of the initial outbreak by providing Covid-19 vaccines to developing countries.
"The Butantan Institute and the Government of Sao Paulo report that the coronavirus vaccine achieved a 50.38% overall efficacy rate in the clinical study conducted in Brazil, in addition to (an efficacy rate of) 78% for mild cases and 100% for moderate and severe cases of Covid-19. All rates are higher than the 50% level required by the WHO (World Health Organization)," the statement released Tuesday said.

The razor-thin margin for regulatory approval is likely to lead to concern among scientists, given that last week the Butantan institute released partial "clinical efficacy" results celebrating 78% to 100% efficacy in preventing infections.

The state body financed the phase 3 trials of the vaccine, which involved 13,000 health workers across eight Brazilian states.
Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.


Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.

"Regarding the overall efficacy of the analysis, we met the requirements of the World Health Organization with 50.38%," Ricardo Palacios, medical director for clinical research at the Butantan biomedical center in Sao Paulo said Tuesday during a news conference.
However, on Tuesday, high-ranking members of the Brazilian Health Ministry told CNN affiliate CNN Brasil that "the effectiveness is borderline," and that because "It is at the limit. We have to wait for ANVISA (Brazilian Health Regulatory Agency) to evaluate."
A representative of Sinovac said the company is discussing the result but declined to give further comment. The final efficacy rate of the vaccine will be determined by China's drug regulator, the National Medical Production Administration, according to the representative.

A much more balanced article


I noticed CNN left out this bit

But Butantan stressed that the vaccine is 78% effective in preventing mild cases that needed treatment and 100% effective in staving off moderate to serious cases.

Butantan is the Brazilian institute conducting the trial.
 

Abdul Baqi

MPA (400+ posts)
I did not say anything. It is an article from CNN. Even the heading is taken from CNN. If you think they are liars then sue them.
CNN and western media is very biased against China. The reason is simple western Europe and America are still picking up dead bodies due to covid while China has kept things in control. Even Australia, NZ, Japan and singapore have kept things normal. no maskers attitude and no vaccine attitude are killing thousands of covid patients in EU and NA daily.
 

Abdul Baqi

MPA (400+ posts)
(CNN)A leading Chinese Covid-19 vaccine developed by Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of Sao Paulo Tuesday.

While the number exceeds the threshold required for regulatory approval, it falls far below the 78% previously announced, raising questions as to the veracity of the data and fueling skepticism over the apparent lack of transparency regarding Chinese vaccines.
Analysts said the efficacy rate of Sinovac's Coronavac vaccine in Brazil -- the lowest among its global competitors -- could affect international confidence in Chinese-made vaccines and hamper Beijing's effort to repair its image from its early mishandling of the initial outbreak by providing Covid-19 vaccines to developing countries.
"The Butantan Institute and the Government of Sao Paulo report that the coronavirus vaccine achieved a 50.38% overall efficacy rate in the clinical study conducted in Brazil, in addition to (an efficacy rate of) 78% for mild cases and 100% for moderate and severe cases of Covid-19. All rates are higher than the 50% level required by the WHO (World Health Organization)," the statement released Tuesday said.

The razor-thin margin for regulatory approval is likely to lead to concern among scientists, given that last week the Butantan institute released partial "clinical efficacy" results celebrating 78% to 100% efficacy in preventing infections.

The state body financed the phase 3 trials of the vaccine, which involved 13,000 health workers across eight Brazilian states.
Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.


Sao Paulo Gov. Joao Doria holds a box of Sinovac's Coronavac vaccine during a news conference on November 19, 2020 in Sao Paulo, Brazil.

"Regarding the overall efficacy of the analysis, we met the requirements of the World Health Organization with 50.38%," Ricardo Palacios, medical director for clinical research at the Butantan biomedical center in Sao Paulo said Tuesday during a news conference.
However, on Tuesday, high-ranking members of the Brazilian Health Ministry told CNN affiliate CNN Brasil that "the effectiveness is borderline," and that because "It is at the limit. We have to wait for ANVISA (Brazilian Health Regulatory Agency) to evaluate."
A representative of Sinovac said the company is discussing the result but declined to give further comment. The final efficacy rate of the vaccine will be determined by China's drug regulator, the National Medical Production Administration, according to the representative.

Due to brazillian mutation just recently detected many vaccines will fail. virus is mutating naturally and this is a reality
 

surfer

Minister (2k+ posts)
Due to brazillian mutation just recently detected many vaccines will fail. virus is mutating naturally and this is a reality
Too early to say. Vaccine may not fail but may be less effective. But from what I understand of the mutations is that it is making it easier to transmit but the effect of the virus is the same?

There were always going to be downsides of fast tracking vaccines, but the world can’t wait another 9 months
 

Abdul Baqi

MPA (400+ posts)
Too early to say. Vaccine may not fail but may be less effective. But from what I understand of the mutations is that it is making it easier to transmit but the effect of the virus is the same?

There were always going to be downsides of fast tracking vaccines, but the world can’t wait another 9 months
brazilian mutation makes past antibody ineffective due to change in shape of the protein and receptors in the newer strain.
 
Sponsored Link

Featured Discussion Latest Blogs اردوخبریں